Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung disease.
Expert Opin Biol Ther
; 4(6): 837-46, 2004 Jun.
Article
em En
| MEDLINE
| ID: mdl-15174966
ABSTRACT
The therapeutic potential of interleukin (IL)-16 and derived peptides in allergic asthma is considered, focusing on key interactions with CD4 and associated chemokine receptors. IL-16 is a pleiotropic cytokine that has multiple effector functions with putative roles in varied T cell-mediated inflammatory diseases, such as asthma, inflammatory bowel disease and atopic dermatitis. Both in vitro and in vivo, IL-16 downregulates antigen-driven T cell activation, T helper 2 cytokine production and allergic airway inflammation. Peptides derived from the C-terminal bioactive portion of IL-16 offer advantages related to their retained immunomodulatory properties and absence of signalling in and chemoattraction to T cells.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Asma
/
Interleucina-16
/
Pneumopatias
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article